I would think only for NSCLC as that is the trial that hopefully gets FDA approval. However as an acquisition of IMM then Merck get the full range of every other trial that is underway. If HNSCC trial is successful prior to the NSCLC then that just bumps up the acquisition price.
Ann: Immutep announces Ph 3 clinical trial collaboration with MSD, page-12
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.0¢ |
Change
0.005(1.49%) |
Mkt cap ! $493.8M | |||
| Open | High | Low | Value | Volume |
| 33.5¢ | 34.0¢ | 33.0¢ | $1.220M | 3.642M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 57289 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.0¢ | 52306 | 3 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |